Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Hochhaus, Andreas; Masszi, Tamás; J. Giles, Francis; P. Radich, Jerald; M. Ross, David; T Gómez Casares, M; Hellmann, Andrzej; Stentoft, Jesper; Conneally, Eibhlin; García‐Gutiérrez, Valentín; Gattermann, Norbert; Wiktor-Jędrzejczak, W; D. le Coutre, Philipp; Martino, B.; Saußele, Susanne; D. Menssen, Hans; Deng, Weiping; Krunic, Nancy; Bédoucha, Véronique; Saglio, Giuseppe

doi:10.1038/leu.2017.63

Public

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Published in Leukemia • Feb 20, 2017

Authors:

Andreas Hochhaus

Tamás Masszi

Francis J. Giles

Abstract

The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic ...

Subject

Nilotinib

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!